Table 3. Comparison of incidences ≥10% of mAb-associated AEs between the treatment groups.
| mAb-associated AEs | IBI305 (N=224) | Bevacizumab (N=226) | |||||
|---|---|---|---|---|---|---|---|
| All grades, n (%) | Grades 1–2, n (%) | Grades 3–4, n (%) | All grades, n (%) | Grades 1–2, n (%) | Grades 3–4, n (%) | ||
| Any grade mAb-associated AEs | 173 (77.2) | 98 (43.8) | 75 (33.5) | 181 (80.1) | 118 (52.2) | 63 (27.9) | |
| Decreased white blood cell count | 54 (24.1) | 32 (14.3) | 22 (9.8) | 47 (20.8) | 32 (14.2) | 15 (6.6) | |
| Decreased neutrophil count | 53 (23.7) | 17 (7.6) | 36 (16.1) | 47 (20.8) | 20 (8.8) | 27 (11.9) | |
| Proteinuria | 52 (23.2) | 52 (23.2) | – | 47 (20.8) | 46 (20.4) | 1 (0.4) | |
| Thrombocytopenia | 50 (22.3) | 33 (14.7) | 17 (7.6) | 36 (15.9) | 26 (11.5) | 10 (4.4) | |
| Anemia | 44 (19.6) | 37 (16.5) | 7 (3.1) | 39 (17.3) | 33 (14.6) | 6 (2.7) | |
| Epistaxis | 25 (11.2) | 24 (10.7) | 1 (0.4) | 31 (13.7) | 31 (13.7) | – | |
| Hypertension | 22 (9.8) | 13 (5.8) | 9 (4.0) | 33 (14.6) | 21 (9.3) | 12 (5.3) | |
| Increased aspartate aminotransferase | 24 (10.7) | 22 (9.8) | 2 (0.9) | 19 (8.4) | 17 (7.5) | 1 (0.4) | |
| Increased alanine aminotransferase | 24 (10.7) | 22 (9.8) | 2 (0.9) | 15 (6.6) | 14 (6.2) | 1 (0.4) | |
mAb, monoclonal antibody; AEs, adverse events.